Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Print1
- Journal1
- Article Type
- Case Reports1
- Result From
- Lane Catalog1
- PubMed1
- SearchWorks (biomedical subset) 1
-
Year
- Journal Title
- Lancet1
Search Results
Sort by
- Journal
- ArticlePierides AM, Alvarez-Ude F, Kerr DN.Lancet. 1975 Dec 27;2(7948):1279-82.Muscle weakness and tenderness together with a rise in serum creatine kinase (C.K.) were noted in five uraemic patients treated with 1-2 g of clofibrate ('Atromid-S') daily. Excessive accumulation of both total and free serum chlorophenoxyisobutyric acid (C.P.I.B.), the active circulating metabolite after clofibrate therapy, was found in three patients in whom it was sought. It is suggested that chronic renal failure should be regarded as a contraindication to the use of clofibrate for the treatment of any coexisting hyperlipidaemia. If such therapy is contemplated it must be cautiously instituted at low dosage and the patient monitored by regular assessment of serum C.K. and levels of both total and free C.P.I.B.